Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.

Keyphrases

• Bacillus Calmette-Guérin 100%
• Mitomycin C 100%
• T1 Bladder Cancer 100%
• Meta-analysis 33%
• Tumor Recurrence 27%
• Disease Progression 22%
• Log Hazard Ratio 22%
• High Risk 11%
• No Significant Difference 11%
• Disease Survival 11%
• Recurrence Risk 5%
• Clinical High Risk 5%
• Subgroup Analysis 5%
• Transurethral Resection 5%
• Data Extraction 5%
• Recurrent Disease 5%
• Overall Survival 5%
• Intravesical Administration 5%
• Adverse Events 5%
• Fever 5%
• Two-agent 5%
• Sensitivity Analysis 5%
• Treatment Toxicity 5%
• MEDLINE 5%
• Cochrane 5%
• Embase 5%
• Systemic Side Effects 5%
• Weighted Mean 5%
• Hematuria 5%
• Systemic Toxicity 5%
• Malaise 5%
• Comprehensive Search 5%
• Methodological Quality 5%
• Dysuria 5%
• Systematic Meta-analysis 5%
• Clinical Problems 5%
• Skin Rash 5%
• Cystitis 5%
• Prophylactic Activity 5%
• Trial Eligibility 5%
• Time-to-event Analysis 5%
• Local Toxicity 5%
• Recurrent Rate 5%
• Patient Risk 5%

Medicine and Dentistry

• Bladder Cancer 100%
• Mycobacterium Bovis BCG 100%
• Mitomycin 100%
• Meta-Analysis 37%
• Tumor Recurrence 31%
• Disease Exacerbation 25%
• Hazard Ratio 25%
• Arm 18%
• Systematic Review 12%
• Recurrent Disease 12%
• Health Care Cost 6%
• Low Drug Dose 6%
• Subgroup Analysis 6%
• Adverse Event 6%
• Exanthem 6%
• Side Effect 6%
• Overall Survival 6%
• Transurethral Resection 6%
• Microhematuria 6%
• Malaise 6%
• Strangury 6%
• Cystitis 6%
• Intravesical Drug Administration 6%
• Chill 6%

Pharmacology, Toxicology and Pharmaceutical Science

• Mitomycin 100%
• Bladder Cancer 100%
• Mycobacterium Bovis BCG 100%
• Tumor Recurrence 31%
• Disease Exacerbation 25%
• Recurrent Disease 12%
• Side Effect 6%
• Adverse Event 6%
• Overall Survival 6%
• Rash 6%
• Malaise 6%
• Cystitis 6%
• Strangury 6%
• Chill 6%